MSB 4.66% $1.13 mesoblast limited

Ann: Trading Halt, page-244

  1. 2,031 Posts.
    lightbulb Created with Sketch. 1178
    Sorry thought I answered this - my reply seems not to have gone through.

    The FDA is key performance indicated against the number of BLAs and BLA resubmissions it manages to do in a a period of a year or so - it has to report on those. This means it has to project manage so as to give itself the best chance to achieve a 6 month response time once it has accepted a resubmission for review.

    Booking and sending inspectors to Singapore would be something necessary to do unless it was already clear the BLA resubmission was going to fail. Presupposing failure - before taking a good look at all the details of the submission would be wrong - so booking and doing an inspection is just necessary to try to ensure the FDA can give a response in 6 months as its supposed to do.

    Reviewing all the info in BLA resubmission critically and fairly is a big project - it has to be handled with critical path analysis for the FDA to meet its time commitments - that why in my opinion.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.13
Change
-0.055(4.66%)
Mkt cap ! $1.284B
Open High Low Value Volume
$1.18 $1.18 $1.13 $4.824M 4.236M

Buyers (Bids)

No. Vol. Price($)
2 25589 $1.13
 

Sellers (Offers)

Price($) Vol. No.
$1.13 10000 1
View Market Depth
Last trade - 16.10pm 17/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.